Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
about
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damageTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyImproving the efficacy of chemoradiation with targeted agentsMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responsePerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerTargeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repairComparative analysis of radiosensitizers for K-RAS mutant rectal cancersUnbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisationSensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD MyoblastsTargeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.NRF2 and p53: Januses in cancer?Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.Targeting the ATR-CHK1 Axis in Cancer TherapyUpregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.Biological determinants of radioresistance and their remediation in pancreatic cancer.WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.ATR/CHK1 inhibitors and cancer therapy.Identification of genes and candidate agents associated with pancreatic cancer.RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
P2860
Q24310132-969F0EF8-E411-44F2-89B3-2DFDC5C64D11Q26745686-264A3DA9-09C3-4339-B8EA-C5E00BEA95F7Q26850193-BEBF4A20-F4F9-4F4B-A534-26594C699715Q27014080-CFD8AA7B-2D81-42FD-BB82-637D4E4D2060Q28066320-34148783-58E0-4524-9BAF-B1422A959DD5Q34055827-57736423-3325-4E58-A409-77D2AB43F125Q34287982-D3A5E58F-D8DE-43AB-9AA3-8CCD499C188EQ34309214-77F58F9A-2358-4AA4-A724-6741C1BD486FQ34777845-D9C1EC5D-8346-4560-9E28-6624A95CB92FQ35070685-FB613703-004D-4814-BC5D-E5D30006E0A2Q35678372-ED0FD6E1-B8E6-4115-991E-B1FA72D788B1Q36088183-4EA2D2C7-3AF8-4EB8-A1E1-80F731021844Q36723763-77567C8E-6F09-4572-8E77-12E43AFA1DCCQ36792626-44459418-2FAB-4737-9C3A-8CF1870DF604Q37100166-72B1CA25-528F-4394-94FF-65EF72A23BC6Q37312029-25C42079-03B4-429E-8255-2051FDD6B002Q37376369-A34CCB86-3AE3-4154-B714-18CF9432D099Q37696310-94A93EF2-AD85-48CE-8922-2C1DB415206BQ38061832-A2BC499E-4550-41CE-901B-B6EA6B598C2FQ38541699-98E5EBCF-D62B-4295-98B0-E4DEA60FCCBAQ38735426-89B3607B-2F1F-44D8-B542-8DD6ED5A8B16Q38773634-B2B2F957-88ED-4E42-B94D-A8B35990C7C7Q38817102-F18A9462-A848-4AFC-A6C4-14655AA17665Q39076159-55F7613A-C39F-4590-AF78-206011D0BF83Q39156722-22F459C7-AB7F-4ACD-A03C-EED6C9831319Q41618744-E8150498-FAB4-48C8-912A-067EBFFC2C0FQ42083096-26596701-A677-4BE5-A6DA-47DD516EDF10Q47622968-AD99F068-FBA6-4C96-A0DB-F8663F1F81A1Q47807955-C0008301-B68E-4D67-889B-51E97B6FB9EDQ50077606-3C2D3958-3105-44C4-85A9-85B674DC5817
P2860
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@ast
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@en
type
label
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@ast
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@en
prefLabel
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@ast
Selective radiosensitization o ...... inhibition of Chk1 and PARP1.
@en
P2093
P2860
P356
P1433
P1476
Selective radiosensitization o ...... d inhibition of Chk1 and PARP1
@en
P2093
Jeffery L Brown
Jonathan Maybaum
Joshua D Parsels
Leslie A Parsels
Meredith A Morgan
Theodore S Lawrence
P2860
P304
P356
10.4161/CC.10.24.18661
P50
P577
2011-12-15T00:00:00Z